These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 11269478)
1. Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer. Kara M; Ohta Y; Tanaka Y; Oda M; Watanabe Y Ann Thorac Surg; 2001 Mar; 71(3):944-8. PubMed ID: 11269478 [TBL] [Abstract][Full Text] [Related]
2. Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas. Kaynak K; Kara M; Oz B; Akgoz B; Sar M; Raz A Acta Chir Belg; 2005 Aug; 105(4):378-82. PubMed ID: 16184720 [TBL] [Abstract][Full Text] [Related]
3. Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer. Takanami I; Takeuchi K; Watanabe H; Yanagawa T; Takagishi K; Raz A Int J Cancer; 2001 Nov; 95(6):384-7. PubMed ID: 11668522 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Endo K; Shirai A; Furukawa M; Yoshizaki T Hum Pathol; 2006 Aug; 37(8):1111-6. PubMed ID: 16867875 [TBL] [Abstract][Full Text] [Related]
5. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125 [TBL] [Abstract][Full Text] [Related]
6. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. Jiang WG; Raz A; Douglas-Jones A; Mansel RE J Histochem Cytochem; 2006 Feb; 54(2):231-41. PubMed ID: 16204225 [TBL] [Abstract][Full Text] [Related]
7. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629 [TBL] [Abstract][Full Text] [Related]
8. Autocrine motility factor receptor: a clinical review. Chiu CG; St-Pierre P; Nabi IR; Wiseman SM Expert Rev Anticancer Ther; 2008 Feb; 8(2):207-17. PubMed ID: 18279062 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610 [TBL] [Abstract][Full Text] [Related]
19. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470 [TBL] [Abstract][Full Text] [Related]
20. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]